Drug Trial Radar · NCT07157956
CVL006 Combination Therapy in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
318
Planned (sponsor's estimate)
Start
Sep 10, 2025
Primary completion
Aug 12, 2028
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Convalife (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multi-center, open-label, dose-escalation and dose-optimized phase I/II clinical trial. Objective: To determine the safety, tolerability, PK characteristics and preliminary efficacy data of CVL006 combined with pemetrexed + carboplatin/SKB264/ DS-8201a/ Enfortumab Vedotin in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
CVL006 combined with pemetrexed and carboplatinDrug
CVL006 combined with pemetrexed and carboplatin
CVL006 in combination with SKB264Drug
CVL006 in combination with SKB264
CVL006 in combination with DS-8201Drug
CVL006 in combination with DS-8201
CVL006 in combination with Enfortumab VedotinDrug
CVL006 in combination with Enfortumab Vedotin
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLT and RP2D of phase ITime frame: 28 days after the first medication; If the second administration is delayed, the DLT observation period will be extended to 14 days after the second administration
- Phase II, progression-free survival (PFS) according to RECISTv1.1 criteriaTime frame: Imaging examinations should be conducted every 8 weeks (±7 days) after the initiation of administration
- Safety endpoints for phase I and Phase IITime frame: From date of randomization until the date of first documented progression, assessed up to 36 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.